Obstructive sleep apnea (OSA) is quite prevalent during pregnancy and is associated with adverse perinatal outcomes, but its potential influence on fetal development remains unclear. This study investigated maternal OSA impact on the fetus by analyzing gene expression profiles in whole cord blood (WCB). Ten women in the third trimester of pregnancy were included, five OSA and five non-OSA cases. WCB RNA expression was analyzed by microarray technology to identify differentially expressed genes (DEGs) under OSA conditions. After data normalization, 3238 genes showed significant differential expression under OSA conditions, with 2690 upregulated genes and 548 downregulated genes. Functional enrichment was conducted using gene set enrichment analysis (GSEA) applied to Gene Ontology annotations. Key biological processes involved in OSA were identified, including response to oxidative stress and hypoxia, apoptosis, insulin response and secretion, and placental development. Moreover, DEGs were confirmed through qPCR analyses in additional WCB samples (7 with OSA and 13 without OSA). This highlighted differential expression of several genes in OSA (EGR1, PFN1 and PRKAR1A), with distinct gene expression profiles observed during rapid eye movement (REM)-OSA in pregnancy (PFN1, UBA52, EGR1, STX4, MYC, JUNB, and MAPKAP). These findings suggest that OSA, particularly during REM sleep, may negatively impact various biological processes during fetal development.
Obstructive sleep apnea (OSA) is common during pregnancy and linked to adverse outcomes. While oxidative stress is a proposed pathogenic mechanism, evidence in pregnant populations remains limited. This multicenter, prospective study evaluated oxidative stress through protein carbonyl levels in 171 pregnant women and 86 cord blood samples. Polysomnography (PSG) performed during pregnancy categorized participants with the apnea–hypopnea index (AHI) in OSA, rapid eye movement (REM) OSA, and supine OSA. Protein carbonyl levels were measured by the dinitrophenyl hydrazine (DNPH) method. No significant differences were found in maternal or cord blood protein carbonyl levels between OSA and non-OSA groups, or between REM and supine OSA subgroups. Interestingly, women with shorter apnea–hypopnea (AH) length showed both higher maternal and cord blood protein carbonyl levels and lower nocturnal oxygen saturation. Overall, OSA in pregnancy was not associated with increased oxidative stress as measured by protein carbonyl levels. However, apnea–hypopnea duration and nocturnal hypoxia may influence oxidative stress, pointing to a complex relationship between OSA and oxidative stress during pregnancy, beyond traditional metrics like AHI. Future studies should explore additional biomarkers and diverse molecular pathways that could play a role, with special attention to emerging factors such as apnea–hypopnea length and hypoxic burden to elucidate the interrelationships between OSA and pregnancy more comprehensively.
Background/Objectives: In our previous systematic review, we found no convincing evidence to support rapid maxillary expansion (RME) as a treatment for pediatric obstructive sleep apnea (OSA). Subsequent clinical guidelines and expert opinion have continued to recommend this orthodontic treatment. We aimed to update our search to determine whether new controlled prospective evidence alters this conclusion. Methods: We updated our previous systematic review, searching for controlled prospective studies on RME efficacy for pediatric OSA published up to 1st February 2026. Results: Three new randomized clinical trials (RCTs) were identified in addition to the five original studies. Critically, none of the new RCTs included a watchful waiting or supportive care control arm, leaving the sole available comparison against watchful waiting unchanged: a single RCT that found no significant difference in AHI change between RME and observation. Of the remaining new RCTs, two found marginal AHI improvement with RME and one found no significant AHI reduction. Conclusions: The observed AHI improvements in studies lacking an untreated comparator cannot be distinguished from the known potential for spontaneous improvement in growing children. Extreme caution is warranted before recommending RME as a treatment for pediatric OSA.
Background: Obstructive sleep apnea (OSA) has been implicated in declarative memory impairment. Here, we evaluated immediate recall and overnight declarative memory in patients with suspected OSA before and after standard clinical management in a longitudinal cohort of 265 patients. Methods: A nocturnal polysomnographic study (PSG) was performed at baseline and repeated six months later. The Pictorial-Based Declarative Memory Questionnaire (PDMQ) was administered and consisted of four learning trials followed by free-recall 10 min before PSG and the following morning upon awakening. The primary cognitive endpoint was the change in pictorial declarative memory performance from baseline to 6-month follow-up, expressed as the number of correctly recalled items on the PDMQ. Results: Both immediate and delayed recall performances significantly improved in the no OSA/mild OSA and severe OSA groups, whereas only immediate recall improved in the moderate OSA group. In the severe group, comparisons between patients whose apnea–hypopnea index decreased to 30 revealed significant cognitive improvements in both subgroups, particularly in initial and late trials (Trials 1, 2, 5, 6). In multivariable models, baseline PDMQ performance and indices of SpO2 desaturation and sleep fragmentation emerged as independent predictors of change in declarative memory. Conclusions: These findings suggest that routine clinical management of patients with OSA was accompanied by modest, albeit statistically significant improvements in declarative memory, and that both intermittent hypoxia and sleep fragmentation play important roles in memory change.